Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Sponsor: Shanghai Jiao Tong University School of Medicine
Summary
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.
Official title: A Phase II-III Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Prostate Cancer
Key Details
Gender
MALE
Age Range
40 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2015-01
Completion Date
2027-12
Last Updated
2026-01-12
Healthy Volunteers
No
Conditions
Interventions
Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin
As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.
Locations (2)
Qilu Hospital of Shandong University
Qingdao, Shandong, China
Zhongshan Hospital
Shanghai, China